

**AMENDMENTS TO THE CLAIMS**

The claim listing below will replace all prior versions of the claims in the application:

- 1-12. (Canceled)
13. (Currently Amended) A method for activating the cell-surface receptor muscle, skeletal, receptor tyrosine kinase (MuSK) in a cell having an abnormal dystrophin-associated protein complex (DAPC), comprising contacting the cell with a biglycan therapeutic in an amount effective to potentiate agrin-induced phosphorylation of the receptor MuSK, wherein the abnormal DAPC is caused by one or more of (i) a mutation in a DAPC component, or (ii) an abnormally lower level of a DAPC component compared to a control cell, wherein the DAPC component is: a dystroglycan, dystrophin, or a sarcoglycan, and wherein the receptor MuSK is activated thereby.
- 14-15. (Canceled)
16. (Original) The method of claim 13, wherein the biglycan therapeutic upregulates utrophin levels.
- 17-31. (Canceled)
32. (Previously presented) The method of claim 13, wherein the biglycan therapeutic is a polypeptide including a biglycan amino acid sequence which is at least about 90% identical to SEQ ID NO: 9.
33. (Canceled)
34. (Previously presented) The method of claim 32, wherein the biglycan amino acid sequence includes one or more Leucine Rich Repeats (LRRs) of human biglycan having SEQ ID NO: 9.
35. (Previously presented) The method of claim 32, wherein the polypeptide is derivatized with one or more glycosaminoglycan (GAG) side chains.
36. (Previously presented) The method of claim 13, wherein the biglycan amino acid sequence is at least about 90% identical to amino acids 38-365 of SEQ ID NO: 9.

37. (Previously presented) The method of claim 36, wherein the biglycan amino acid sequence is at least about 95% identical to amino acids 38-365 of SEQ ID NO: 9.
38. (Previously presented) The method of claim 32, wherein the cell is a muscle cell.
39. (Currently Amended) The method of claim 13, further comprising assaying activity of the receptor MuSK, wherein the assay for the receptor MuSK activity comprises determining the phosphorylation state of the receptor MuSK.
40. (Previously Presented) The method of claim 13, wherein the biglycan therapeutic binds to alpha-sarcoglycan and gamma-sarcoglycan.
41. (Previously Presented) The method of claim 13, wherein the biglycan therapeutic stimulates phosphorylation of alpha-sarcoglycan on a cell membrane.
42. (Previously Presented) The method of claim 32, wherein the biglycan amino acid sequence is identical to amino acids 38-365 of SEQ ID NO: 9.
43. (Previously Presented) The method of claim 32, wherein the biglycan amino acid sequence is encoded by a nucleic acid which hybridizes under stringent conditions of 6.0 x sodium chloride/sodium citrate (SSC) at about 45 °C to a complementary strand of SEQ ID NO: 8.
44. (Previously presented) The method of claim 13, wherein the biglycan therapeutic stabilizes dystrophin-associated protein complexes (DAPCs) on the cell surface.
- 45-56. (Cancelled)